Capecitabine and oxaliplatin for advanced esophagogastric cancer.
By D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, A. Norman. New England Journal of Medicine, 2008
1,984 citations recorded by the source corpus.
Subfields: Otorhinolaryngology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/81cef03b8902db09435cdd95c6854a851df384ba
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Otorhinolaryngology
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. (2009, background): “REAL-2 recently demonstrated that capecitabine can replace 5-FU when used as part of a triple combination regimen in patients with AGC [14].”
- Japanese gastric cancer treatment guidelines 2014 (ver. 4) (2016, result): “(Additional comments in this English edition) Following the results of the SOX-GC trial [22] and REAL2 trial [23], S-1 plus oxaliplatin or capecitabine plus oxaliplatin became options for the first-line chemotherapy and is tentatively rated as recommendation category 2.”
- Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, background): “Newer regimens based on oxaliplatin/ fluoropyrimidine combinations are an alternative to the ‘classical’ cisplatin/5-FU schedule [26].”
- Japanese gastric cancer treatment guidelines 2018 (5th edition) (2020, neutral): “CapeOX, a combination of capecitabine and oxaliplatin which was approved in 2014 in Japan, has shown efficacy that is at least equivalent to the FP in the subset analysis of a phase III study (no Japanese patients included) which evaluated triplets that combined these regimens with epirubicin (Evide”
- Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) (2022, methodology): “CapeOX, a combination of capecitabine and oxaliplatin that was approved in 2014 in Japan, has efficacy that is at least equivalent to the FP shown in the subset analysis of a phase III study (no Japanese patients included) that evaluated triplets that combined these regimens with epirubicin [52].”